This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

44/100

✓ Peer-reviewed alzhub usefulness score 44 out of 100. Brain tissue and pathology

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

There is increasing evidence that deficient clearance of β-amyloid (Aβ) contributes to its accumulation in late-onset Alzheimer disease (AD). Several Aβ-degrading enzymes, including neprilysin (NEP), insulin-degrading enzyme, and endothelin-converting enzyme reduce Aβ levels and protect against cognitive impairment in mouse models of AD. The activity of several Aβ-degrading enzymes rises with age and increases still further in AD, perhaps as a physiological response to minimize the buildup of Aβ.

What this study adds

Evidence grade: Low

This is a narrative review. This paper reviews amyloid-beta-degrading enzymes that reduce amyloid-beta levels and protect against cognitive impairment in mouse models of Alzheimer's disease. The evidence comes from animal models, and the age- and disease-related changes in expression of some of these enzymes remain to be determined.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Miners, J. S., Barua, N., Kehoe, P. G., Gill, S., & Love, S. (2011). Aβ-degrading enzymes: potential for treatment of Alzheimer disease. Journal of neuropathology and experimental neurology. https://doi.org/10.1097/nen.0b013e3182345e46

Vancouver

Miners JS, Barua N, Kehoe PG, Gill S, Love S. Aβ-degrading enzymes: potential for treatment of Alzheimer disease. Journal of neuropathology and experimental neurology. 2011. doi:10.1097/nen.0b013e3182345e46. PMID: 22002425.

BibTeX

@article{miners2011-22002425,
  author  = {Miners, J. S. and Barua, N. and Kehoe, P. G. and Gill, S. and Love, S.},
  title   = {{Aβ-degrading enzymes: potential for treatment of Alzheimer disease}},
  journal = {Journal of neuropathology and experimental neurology},
  year    = {2011},
  doi     = {10.1097/nen.0b013e3182345e46},
  pmid    = {22002425},
  url     = {https://doi.org/10.1097/nen.0b013e3182345e46}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

How to read this study

Design: this is a narrative review. It summarises a field without a fixed search method, so it shows how authors read the evidence rather than measuring it. Use it to find the primary studies, not as a result in itself.
Size: the record gives no participant count. Look for one in the original before trusting a pattern.
Effect: the record gives no effect size, so the summary above cannot say how large any difference was.

What the evidence grade means here

This page is graded low. alzhub.org assigns the grade automatically from keywords in the abstract, not from reading the paper. Low means the abstract matched neither pattern. It is the default label, and it does not mean the work is poor; many sound lab and imaging papers land here. It can add at most 5 of the 100 points in the study score, and it is a label about design, not a verdict on whether the findings are true.

New to reading papers? Six questions to ask of any Alzheimer’s study · how we score.

Key findings

Several Aβ-degrading enzymes, including neprilysin (NEP), insulin-degrading enzyme, and endothelin-converting enzyme reduce Aβ levels and protect against cognitive impairment in mouse models of AD.
The activity of several Aβ-degrading enzymes rises with age and increases still further in AD, perhaps as a physiological response to minimize the buildup of Aβ.
The age- and disease-related changes in expression of more recently recognized Aβ-degrading enzymes (e.g.
NEP-2 and cathepsin B) remain to be investigated, and there is strong evidence that reduced NEP activity contributes to the development of cerebral amyloid angiopathy.

Why it matters

This paper reviews amyloid-beta-degrading enzymes that reduce amyloid-beta levels and protect against cognitive impairment in mouse models of Alzheimer's disease. The evidence comes from animal models, and the age- and disease-related changes in expression of some of these enzymes remain to be determined.

Study details

Evidence strengthLow

How this study scored 44/100

Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.

Component	Points	Why
Journal tier	7 / 10	Tier 3 — peer-reviewed journal (Journal of neuropathology and experimental neurology)
Journal's citation record	2 / 4	Journal of Neuropathology & Experimental Neurology: journal h-index 239 (OpenAlex, 2026-10-29)
Study design	0 / 12	No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence	1 / 5	Rated “low” in our summary
Peer-review validation	10 / 10	Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent	1 / 5	2011 — within 20 year(s) of the newest study here
Sample size	0 / 4	Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported	0 / 3	No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people	0 / 3	Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomized / blinded	0 / 2	No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited	5 / 7	Cited 265 times (OpenAlex, 2026-10-10)
Citations per year	3 / 5	15.6 citations a year over 17 year(s) since 2011
Impact for its field and year	4 / 6	Cited 14.9× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here	2 / 6	Cited by 5 other studies in this library
Still being cited	2 / 4	Cited 29 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record	3 / 4	Last-listed author Seth Love: h-index 90 (OpenAlex, whole career)
Institution's track record	1 / 3	University of Bristol: institution h-index 1,260 (OpenAlex)
Multicenter collaboration	1 / 3	OpenAlex lists 2 institution(s) in 1 country
Indexed in PubMed	2 / 2	Indexed in PubMed (PMID 22002425)
Free to read	0 / 2	Behind a paywall — scores zero
Total	44 / 100	—

What each of these 20 components measures, and what this score is not →

Read the original

May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it. The PubMed abstract is free.

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 24.

Later studies that cite this one

5 studies in the alzhub library list this one in their references.

Related studies in Brain tissue and pathology from nearby years

Also in Brain tissue and pathology

124 studies in the library are filed under Brain tissue and pathology with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Brain tissue and pathology hub.

Similar studies

More on Brain tissue and pathology

See all studies in Brain tissue and pathology →